Medicus Pharma is progressing its precision oncology pipeline with a focus on clinical and regulatory milestones, aiming to secure partnerships and licensing deals to support development. The company's lead candidate, CD228V, targets melanoma and other cancers, while the FDA has approved a new study for SkinJect in Gorlin syndrome patients. Additionally, Medicus is advancing Teverelix in urology and women's health, with plans for partnership-driven development in prostate cancer. Since inception, Medicus has raised about $90 million to fund clinical trials, acquisitions, and operations, positioning itself for growth through collaboration and focused clinical progress.
Medicus Pharma's oncology pipeline progress is the subject here. For readers following the health sector, of 128 priced US health stocks tradable on Pluang, 34 rose and 88 fell today. Notable movers include TXG at USD 73.46 with a -3.47% change and 74% sell order activity, MESO at USD 13.48 down 3.30%, and SANA at USD 2.80 up 2.94% with 73% buy order activity. This data is as of Oct 08, 2026 19:42 WIB.
CIQ has released Fuzzball 4.3, a platform that enables enterprises to deploy validated open-weight AI models and agents on their existing GPU infrastructure with a single command. This update simplifies operationalizing AI by automatically connecting...
As of September 30, 2026, Societe Generale's share capital consists of 739,264,232 shares with a total of 821,169,560 voting rights. The bank highlights its strong global presence with 110,000 employees serving 27 million clients across 58 countries....
Weyerhaeuser's stock recently dropped to a new 52-week low of $18.31, trading around $18.51, reflecting market pressure. Analysts have mixed views: Seaport Global lowered its price target to $30, Raymond James upgraded to "strong buy" with the same t...
Canadian Utilities and Emera have agreed to merge as equals, creating a larger utility and energy infrastructure company. RBC Capital maintains a 'Sector Perform' rating on Canadian Utilities, indicating expected performance in line with the sector. ...
Domino's Pizza is set to report its Q3 earnings on October 13, 2026, with analysts forecasting earnings per share between $4.33 and $4.36 and revenue around $1.17 billion, a 1.6% increase year-over-year. Investors will watch closely how promotional d...
